Nicole C A J Van De Kar

List of Publications by Year
in descending order

81 papers	3,458 citations	201674 27 h-index	144013 57 g-index
88 all docs	88 docs citations	88 times ranked	2803 citing authors

#	Article	IF	Citations
1	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrology Dialysis Transplantation, 2023, 38, 362-371.	0.7	3
2	A clinical approach to children with C3 glomerulopathy. Pediatric Nephrology, 2022, 37, 521-535.	1.7	9
3	Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatric Nephrology, 2022, 37, 601-612.	1.7	3
4	Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling. Development (Cambridge), 2022, 149, .	2.5	16
5	The potential of individualized dosing of ravulizumab to improve patientâ€friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs. British Journal of Clinical Pharmacology, 2021, 87, 3359-3363.	2.4	6
6	Cell Biological Responses after Shiga Toxin-1 Exposure to Primary Human Glomerular Microvascular Endothelial Cells from Pediatric and Adult Origin. International Journal of Molecular Sciences, 2021, 22, 5615.	4.1	2
7	Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome. Kidney International, 2021, 100, 265-268.	5.2	4
8	Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 715704.	4.8	5
9	Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity. Methods in Molecular Biology, 2021, 2227, 83-96.	0.9	2
10	Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. CKJ: Clinical Kidney Journal, 2021, 14, 1939-1945.	2.9	5
11	The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway. Journal of Immunology, 2021, 207, 2465-2472.	0.8	5
12	The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS. Microorganisms, 2021, 9, 2157.	3.6	6
13	Shiga Toxin 2a Induces NETosis via NOX-Dependent Pathway. Biomedicines, 2021, 9, 1807.	3.2	4
14	Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium. Toxins, 2020, 12, 435.	3.4	3
15	Primary Human Derived Blood Outgrowth Endothelial Cells: An Appropriate In Vitro Model to Study Shiga Toxin Mediated Damage of Endothelial Cells. Toxins, 2020, 12, 483.	3.4	4
16	Heme as Possible Contributing Factor in the Evolvement of Shiga-Toxin Escherichia coli Induced Hemolytic-Uremic Syndrome. Frontiers in Immunology, 2020, 11, 547406.	4.8	5
17	Authorâ€™s Reply to Liu et al.: â€œPharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumabâ€• Clinical Pharmacokinetics, 2020, 59, 1645-1646.	3.5	0
18	Preparing for a kidney transplant: Medical nephrectomy in children with nephrotic syndrome. Pediatric Transplantation, 2020, 24, e13703.	1.0	4

#	Article	IF	Citations
19	The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment. Cellular and Molecular Immunology, 2020, 17, 653-655.	10.5	6
20	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Frontiers in Immunology, 2020, 11, 612706.	4.8	9
21	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?. Pediatric Nephrology, 2020, 35, 1791-1795.	1.7	1
22	The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?. Pediatric Nephrology, 2019, 34, 1349-1367.	1.7	15
23	Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. Frontiers in Immunology, 2019, 10, 1350.	4.8	15
24	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	3.5	82
25	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatric Nephrology, 2019, 34, 2261-2277.	1.7	60
26	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient, 2019, 12, 149-162.	2.7	10
27	Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157. Pediatric Nephrology, 2019, 34, 631-639.	1.7	7
28	Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrology Dialysis Transplantation, 2018, 33, 635-645.	0.7	36
29	Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome. Journal of Human Genetics, 2018, 63, 93-96.	2.3	4
30	The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik, 2018, 30, 400-409.	0.2	33
31	Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy. American Journal of Kidney Diseases, 2018, 72, 906.	1.9	2
32	SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. Nephrology Dialysis Transplantation, 2018, 33, i322-i322.	0.7	1
33	Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Frontiers in Immunology, 2018, 9, 612.	4.8	30
34	Clinical and genetic analyses of a Dutch cohort of 40 patients with a nephronophthisis-related ciliopathy. Pediatric Nephrology, 2018, 33, 1701-1712.	1.7	20
35	Re: Bevill et al.: The Modern Metabolic Stone Evaluation in Children (Urology 2017;101:15-20). Urology, 2017, 102, 267-268.	1.0	0
36	Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatric Nephrology, 2017, 32, 1263-1268.	1.7	27

#	Article	IF	Citations
37	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient, 2017, 10, 629-642.	2.7	14
38	Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. American Journal of Kidney Diseases, 2017, 70, 770-777.	1.9	46
39	Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatric Nephrology, 2017, 32, 297-309.	1.7	48
40	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. Immunobiology, 2016, 221, 1141.	1.9	1
41	Drug-Drug Interactions in Treatment Using Azole Antifungal Agents. JAMA - Journal of the American Medical Association, 2016, 315, 2622.	7.4	0
42	Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatric Nephrology, 2016, 31, 2163-2170.	1.7	27
43	Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International, 2016, 89, 701-711.	5.2	210
44	Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease. Journal of Infectious Diseases, 2016, 213, 1820-1827.	4.0	17
45	A young girl with an unusual cause of acute kidney injury: Questions. Pediatric Nephrology, 2016, 31, 2071-2073.	1.7	0
46	A young girl with an unusual cause of acute kidney injury: Answers. Pediatric Nephrology, 2016, 31, 2075-2078.	1.7	1
47	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	1.7	445
48	Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo. Blood, 2015, 126, 278-279.	1.4	17
49	Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2015, 65, 342.	1.9	35
50	Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology, 2015, 160, 237-243.	3.2	42
51	Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Therapeutic Advances in Hematology, 2015, 6, 171-185.	2.5	15
52	Refractory thrombotic thrombocytopenic purpura in a 16â€yearâ€old girl: successful treatment with bortezomib. European Journal of Haematology, 2014, 92, 80-82.	2.2	40
53	Severe infantile Bordetella pertussis pneumonia in monozygotic twins with a congenital C3 deficiency. European Journal of Pediatrics, 2014, 173, 1591-1594.	2.7	7
54	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1967-1978.	1.7	95

#	Article	IF	Citations
55	Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrology Dialysis Transplantation, 2014, 29, iv131-iv141.	0.7	65
56	Compound heterozygous mutations in the C6 gene of a child with recurrent infections. Molecular Immunology, 2014, 58, 201-205.	2.2	14
57	Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives. Microbiology Spectrum, 2014, 2, EHEC-0025-2014.	3.0	51
58	Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update. Blood, 2014, 124, 4986-4986.	1.4	2
59	The challenge of managing hemophilia A and STEC-induced hemolytic uremic syndrome. Pediatric Nephrology, 2013, 28, 349-352.	1.7	1
60	Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: A case report and review of the literature. International Journal of Hygiene and Environmental Health, 2013, 216, 211-213.	4.3	19
61	Adult Renal Size is Not a Suitable Marker for Nephron Numbers: An Individual Patient Data Meta-Analysis. Kidney and Blood Pressure Research, 2013, 37, 540-546.	2.0	21
62	Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. Journal of Human Genetics, 2012, 57, 459-464.	2.3	43
63	Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatric Nephrology, 2012, 27, 1519-1524.	1.7	38
64	Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatric Nephrology, 2012, 27, 1193-1195.	1.7	31
65	Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatric Nephrology, 2012, 27, 1283-1291.	1.7	135
66	Unexplained hypothermia and bradycardia in two pediatric patients with Wegenerâ€™s granulomatosis. Pediatric Nephrology, 2011, 26, 325-326.	1.7	2
67	Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrology Dialysis Transplantation, 2010, 25, 2195-2202.	0.7	79
68	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology, 2009, 24, 687-696.	1.7	315
69	A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatric Nephrology, 2007, 22, 371-375.	1.7	33
70	Intraperitoneal treatment with darbepoetin for children on peritoneal dialysis. Pediatric Nephrology, 2007, 22, 436-440.	1.7	7
71	Diagnosis of abdominal aortic hypoplasia by state-of-the-art MR angiography. Pediatric Radiology, 2006, 36, 57-60.	2.0	11
72	Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2006, 32, 113-120.	2.7	91

#	Article	IF	Citations
73	Refractory severe intestinal vasculitis due to Henoch-SchÃ¶nlein Purpura: successful treatment with plasmapheresis. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 622-623.	1.5	14
74	Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatric Nephrology, 2005, 20, 374-379.	1.7	66
75	Mutation analysis and clinical implications of von Willebrand factorâ€“cleaving protease deficiency. Kidney International, 2003, 63, 1995-1999.	5.2	83
76	Increased Arterial Stiffness in Young Adults with End-Stage Renal Disease since Childhood. Journal of the American Society of Nephrology: JASN, 2002, 13, 2953-2961.	6.1	93
77	Local Fibrinolytic Therapy with Urokinase for Peritoneal Dialysis Catheter Obstruction in Children. Peritoneal Dialysis International, 2002, 22, 84-86.	2.3	17
78	Long-Term Effectiveness of Intraperitoneal Erythropoietin in Children on Nipd by Administration in Small Bags. Peritoneal Dialysis International, 2001, 21, 197-199.	2.3	5
79	Verocytotoxin-producing Escherichia coli infection in household members of children with hemolytic-uremic syndrome in the Netherlands. Pediatric Infectious Disease Journal, 1999, 18, 709-714.	2.0	18
80	Effects of TNFÎ± on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney International, 1997, 51, 1245-1256.	5.2	182
81	Shiga Toxin/Verocytotoxin-ProducingEscherichia coliInfections: Practical Clinical Perspectives. , 0, , 297-319.		0